In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astex Therapeutics Ltd.

Division of Otsuka Holdings Co. Ltd.

Latest From Astex Therapeutics Ltd.

Astex Eyes First Filing For Oral Decitabine On Positive Combo Results

Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.

Cancer Clinical Trials

Convergence appoints John Aston to board

Ion channel drug discovery and development company Convergence has appointed John Aston OBE to its board as a non-executive director. Mr Aston was previously CFO of Cambridge Antibody Technology for 10 years before its sale to AstraZeneca for $1.3bn in 2006. He then served as CFO of Astex Therapeutics.

Otsuka closes Astex acquisition despite last minute detractor

Otsuka Pharmaceutical has completed its acquisition of the cancer and CNS focused US firm Astex Pharmaceuticals following a successful tender offer, in a transaction valued at around $886m.


Astex's 'unique' ops to remain intact after Otsuka acquisition

The number of cases where small drug discovery firms have been stripped back to their core assets following a Big Pharma acquisition are too numerous to count, but all the indications are that Otsuka plans to keep the operations and staff of intended new group member Astex Pharmaceuticals intact.

See All

Company Information